Additionally, ceruloplasmin is a predictive biomarker of PAX8 activity, and renal cell carcinoma (RCC) patients with high ceruloplasmin expression have a poor survival rate independent of genetic aberrations [41]. This evidence concerns the gene PAX8 and renal cell carcinoma.